Evidence map›Paper›PMID 41917408›Full record

ReviewAdvances in experimental medicine and biology2026

Influenza Virus Neuraminidase Glycoprotein, Its Inhibitors, and Their Resistance.

Emi Takashita

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Emi TakashitaInfluenza Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan. emitaka@niid.go.jp.ORCID https://orcid.org/0000-0002-9064-4699

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The neuraminidase (NA) glycoprotein of influenza virus plays a critical role in the release of progeny viruses and their spread, making it an important target for antiviral drugs. This chapter provides an overview of the structure and function of NA and of four NA inhibitors-zanamivir, oseltamivir, peramivir, and laninamivir-that are widely used for the treatment and prophylaxis of influenza A and B viral infections. The importance of monitoring the emergence and global spread of NA inhibitor-resistant viruses is also discussed.

Indexed as

Antiviral AgentsDrug Resistance, ViralEnzyme InhibitorsInfluenza A virusInfluenza B virusInfluenza, HumanNeuraminidaseViral ProteinsAcids, CarbocyclicAnimalsCyclopentanesGuanidinesHumansOseltamivirSialic AcidsZanamivirAcids, CarbocyclicAntiviral AgentsCyclopentanesEnzyme InhibitorsGuanidinesNeuraminidaseOseltamivirperamivirSialic AcidsViral ProteinsZanamivirAntiviral drugDrug resistanceInfluenzaNeuraminidaseNeuraminidase inhibitor

Identifiers

PMID41917408

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.